BRD2 and myeloid sarcoma: Natalizumab (NAT, Biogen Idec Inc, Cambridge, Massachusetts, USA) is a monoclonal antibody that was approved in 2004 for the treatment of active relapsing–remitting multiple sclerosis (MS) [1].